Blog

Cristian Massacesi: Visiting our AstraZeneca team in Germany to talk oncology ambitions

Cristian Massacesi/LinkedIn

Apr 19, 2025, 16:12

Cristian Massacesi: Visiting our AstraZeneca team in Germany to talk oncology ambitions

Cristian Massacesi, Chief Medical Officer and Oncology Chief Development Officer at AstraZeneca, shared a post on LinkedIn:

“Recently, I was able to visit members of our AstraZeneca team in Germany to have discussions around our evolving pipeline and how Germany will continue to serve as an integral part of our overarching ambitions in oncology.

The strides being made across the country in clinical trials has been nothing short of inspiring, with three straight years of double-digit growth in patients enrolled in active trials, reflecting our commitment of making clinical trials more accessible throughout the world.

As we continue our ambitions for 2030 and beyond, it’s ever more critical to partner with key stakeholders early in the development process to create better understandings of how clinical trial data collected will be perceived and ensuring it will resonate with the needs of the patients an investigational medicine is intended to treat.

In Germany, we are projecting an increase of more than 35% in patients enrolled in active studies by the end of 2025, while increasing the number of active clinical trial sites throughout the country by nearly 40% (from 2022), making it easier for patients to participate in trials regardless of where they live.

Recognizing the importance of partnerships with clinical trial sites, I was thrilled to have the opportunity to visit the IKF-Institute for Clinical Cancer Research at the Nordwest Clinic Frankfurt where I met with Prof. Thorsten Götze to discuss ongoing clinical trials and gain insights into what more AstraZeneca can do to make clinical trials more accessible for patients. Thank you, Thorsten, for your hospitality.

I look forward to many more visits like these with our teams throughout 2025. By collaborating with the global scientific community, we are able to break down barriers to treatment access while progressing scientific research forward for patients throughout the world.”

More posts featuring Cristian Massacesi.